POSTER High Content Analysis of 2D and 3D cellular models for target and phenotypic drug discovery Lachize, et al. 2020. Courtesy of Charles River Summary Charles River Laboratories (CRL) has developed many disease-relevant cellular models to screen small molecules...
POSTER Optimized reprogramming of human iPSCs to generate distinct neuronal subtypes Karim, et al. 2020. bit.bio Summary A robust source of human iPSC-derived neurons would offer an attractive in vitro model for CNS research and high content drug screens. However,...
VIDEO Accelerating in vitro target and drug discovery using reprogrammed glutamatergic neurons Dr Shushant Jain, Group Leader, in vitro Biology, Discovery. 2020.Charles River at SLAS Summary In this video, Dr Shushant Jain, group leader from Charles River...
WEBINAR Advances in cellular reprogramming: from stem cells to printed tissues Prof Hagan Bayley, University of Oxford & Dr Mark Kotter, Founder & CEO bit.bio. 2020 Summary A scalable technology platform capable of producing consistent batches of every human...
POSTER Molecular and functional characterization of stem cells-derived glutamatergic neurons in support of drug discovery applications Iovino, et al. 2019. Courtesy of Charles River Summary Charles River has performed molecular and functional characterization of human...
Leading clinical immunotherapies developer Ramy Ibrahim joins bit.bio as Chief Medical Officer
bit.bio CEO discusses opti-ox™ technology and the work of bit.bio on BBC Click
Can We Recreate Every Human Cell Type In The Body? This UK Startup Thinks So
Bit.Bio: British firm cracks code for stem cells
bit.bio joins forces with maths institute to find the ‘operating system of life’